SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (3152)6/2/1999 12:36:00 PM
From: quidditch  Read Replies (1) of 10280
 
Peter: Your second para addressed my question. And I did not mean to imply that FDA inquiry would have any impact on licensing or other arrangements outside US.

Do you know what the terms of co-promotion and/or royalty arrangements might be between PFE and UBC? Presumably, these might serve as a guide, but would not control, any terms of a PFE/SEPR deal.

Good point on the clinical data. I would think UBC's consent could only help promote the world-wide franchise that it would like to think it has in the drug. SEPR's own experience with its ICE clinical data, and ultimately trials here (assuming they are conducted in part before the ICE is cleared for marketing in Europe) would seem to contribute complementary data to UBC.

Regards. Steven
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News